Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study

X
Trial Profile

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel; Fludeoxyglucose F-18; Letrozole; Tamoxifen
  • Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms PHERGain
  • Most Recent Events

    • 04 Jun 2024 Results (n=284) of an exploratory analysis comparing between PET response and MRI reduction in terms of pCR and 3-y iDFS from group B of this trial presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2024 According to a MEDSIR media release, sub-analysis data from this trial presented during the 2024 ASCO Annual Meeting.
    • 01 May 2024 Results performing the secondary preplanned analysis of the best cutoff of DELTASUVmax for pCR predictionin HER2-positive early breast cancer patients treated exclusively with neoadjuvant trastuzumab and pertuzumab, published in the Journal of Nuclear Medicine
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top